Treatment of patients with metastatic colorectal cancer with bevacizumab, an anti-VEGF monoclonal antibody, has shown a clear synergy with chemotherapy, supporting the high angiogenic activity measured in our studies of primary colorectal cancer and its metastases in the liver (Kabbinavar et al, 2003). The gene discussed is VEGFA; the disease is metastatic colorectal cancer.